BCR and leukemia: The introduction of ABL1-directed TKIs has dramatically improved the hematological, cytogenetic and molecular responses of leukemia patients displaying a BCR-ABL1 chimeric fusion (Hochhaus et al., 2017; Ottmann et al., 2018; Saglio et al., 2018).